Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : E28362
Catalog No.: PC-22461Not For Human Use, Lab Use Only.
E28362 is a novel small-molecule PCSK9 inhibitor, effectively binds to PCSK9 (SPR KD=14.8 uM) and disrupts the PCSK9-LDLR interaction, promotes the degradation of PCSK9 via the ubiquitin-proteasome pathway.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
E28362 is a novel small-molecule PCSK9 inhibitor, effectively binds to PCSK9 (SPR KD=14.8 uM) and disrupts the PCSK9-LDLR interaction, promotes the degradation of PCSK9 via the ubiquitin-proteasome pathway.
E28362 (5, 10, 20 μM) could significantly increase the intake of DiI-LDL in AML12 cells, with no obvious toxicity.
E28362 increases the LDLR protein level in HepG2 and AML12 cells.
E28362 (6.7, 20, or 60 mg/kg per day) for 4 weeks improves dyslipidemia and decreases hepatic lipid accumulation in HFD-induced golden hamsters.
E28362 (30 or 60 mg/kg per day) for 12 weeks inhibits the development of atherosclerosis in ApoE−/− mice.
E28362 induces PCSK9 degradation through the ubiquitin-proteasome pathway after binding to PCSK9 in hepatic cells.
E28362 decreased PCSK9 levels and alleviated the development of atherosclerosis in PCSK9 overexpression mice.
| M.Wt | 301.35 | |
| Formula | C16H19N3O3 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Wei-Zhi Wang, et al. Acta Pharmacol Sin. 2024 May 29. doi: 10.1038/s41401-024-01305-9.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
